secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2021-08-02T23:59:59+00:00
Accession:  0001558370-21-009752
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q2 net loss $78.5M; UKONIQ revenue $1.5M; U2 PDUFA March 2022
-----------------------------------------------------------------------------

- Net loss $78.5M for Q2 2021, up from $52.9M in Q2 2020; ex-stock comp net loss ~$62.2M.
- UKONIQ net revenue $1.5M in Q2 (total $2.3M since Feb 2021 launch); product revenue zero year ago.
- FDA accepted BLA/sNDA for U2 (ublituximab+UKONIQ) in CLL/SLL; PDUFA goal date March 25, 2022.
- Cash $456.2M at June 30, 2021; company expects to fund operations into 2023.
- Plan to submit BLA for ublituximab in relapsing MS in Q3 2021 based on positive Phase 3 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/0001558370-21-009752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/tgtx-20210802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-009752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer